Navigation Links
Minnesota partnership advances potential MS therapy
Date:4/17/2008

ROCHESTER/MINNEAPOLIS, Minn. A production laboratory founded by the Minnesota Partnership has transferred its first potential therapy a medication for multiple sclerosis to a processing plant in Minnesota. This step will complete purification of material to fully enable translation from preclinical to clinical development.

The antibody known as rHIgM22, developed at Mayo Clinic, was produced and purified in the Biotherapeutic Protein Production Laboratory created by a Partnership infrastructure award in 2006. This laboratory was developed within the Molecular and Cellular Therapeutics Facility on the St. Paul campus of the University of Minnesota. The therapy is under license to Acorda Therapeutics, Inc. (NASDAQ: ACOR), which is supporting the development of this potential therapy. This includes the Minnesota Partnerships transfer of remaining production and purification to Biovest, Inc., in Minneapolis.

The preclinical success and the promise of this program to date have only enhanced our commitment to the continued advancement of this potential new therapy for people with multiple sclerosis, says Ron Cohen, M.D., Acorda president and CEO. The Partnership has provided a mechanism for academic and commercial institutions to work together effectively in the early stages of developing a promising and innovative therapeutic approach to a very challenging condition.

The importance of the antibody as a promoter of myelin repair (remyelination) was recognized in studies using experimental animal models of multiple sclerosis. The studies were directed by Moses Rodriguez, M.D., a Mayo Clinic neurologist. Multiple sclerosis is a progressive disease, caused by damage to the myelin sheath that surrounds nerves. It can affect the brain and the spinal cord, leaving patients permanently disabled. The rHIgM22 antibody initiates the re-growth or repair of the damaged myelin sheath but has yet to be tested in patients.

The initial synthetic production of the therapeutic antibody was developed in the laboratory of Larry Pease, Ph.D., chair of immunology at Mayo. Early stage process development was also performed in collaboration with Acorda Therapeutics. The Partnership facility subsequently developed production of the antibody into a validated process that can be used to produce antibody for patient studies. John Wagner, M.D., at the University of Minnesota, and Dr. Pease were the principal investigators on the Minnesota Partnership grant. The grant established the protein production facility with the mission of providing good manufacturing (GMP) technical support to investigators at the University of Minnesota and Mayo Clinic to move laboratory advancements into clinical trials. The developmental work on this antibody at the protein production facility was funded by philanthropic gifts from the Eugene Applebaum Family Foundation, the Conrad N. Hilton Foundation, and anonymous benefactors.

The Minnesota Partnership was instrumental in providing the infrastructure to develop this monoclonal antibody to this point, says Dr. Pease. This antibody would not be headed into clinical studies or toward commercialization otherwise.

This is exactly what the Partnership is intended to do, says program director Eric Wieben, Ph.D. That is to promote interactions between the two leading medical research institutions in Minnesota and to accelerate medical discoveries that can be commercialized for the benefit of patients while improving our states economy.


'/>"/>

Contact: Nick Hanson
hans2853@umn.edu
612-624-2449
University of Minnesota
Source:Eurekalert

Related medicine news :

1. Securians Minnesota Life Continues to Climb Group Life Rankings
2. Fresh Air Campaign to Showcase Minnesotans Love of Smoke-Free Air
3. Four Minnesota Hospitals Rate High For Patient Safety and Quality
4. First-in-the-Nation Health Care Billing Policy Announced in Minnesota
5. Help is Available for Smokers Who Want to Quit as Minnesotas Smoke-Free Law Takes Effect Oct. 1
6. Maryland, Minnesota Go Smoke-free Oct. 1 - Pennsylvania Overdue in Following Suit
7. New National Medicaid Study: Minnesota Under Funds Seniors Nursing Home Care $167 Million Annually
8. Blue Cross and Partners to Host Combat Stress Conference for Minnesotas Health Care Professionals
9. TV Documentary Examines Three Decades of Tobacco Politics, Policies and People in Minnesota
10. Minneapolis Hosts National Conference on Tobacco or Health October 24-26 on Heels of Minnesotas Statewide, Smoke-Free Law
11. Mayo Clinic Calls for Thorough Review of Canadian Pacifics Acquisition of the Dakota, Minnesota & Eastern Railroad
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated ... latest FDA requirements, which stipulates new criteria regarding medical device manufacture ... Medical ID jewelry such as Medical ID Bracelets, can rest assured ... of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process ...
(Date:10/11/2017)... 11, 2017  Caris Life Sciences ® , a ... promise of precision medicine, today announced that St. Jude ... Oncology Alliance™ (POA) as its 17 th member. ... Jude Crosson Cancer Institute will help develop standards of ... tumor profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)... COUNTY, Calif. , Oct. 10, 2017  NDS received FDA ... Mobile  — a medical-grade battery-powered display stand specifically designed for endoscopy ... to transform technology into a clinical solution to support the improvement ... Innovative Design ... ZeroWire Mobile Wireless Solution ...
Breaking Medicine Technology: